過去のRFP
GHIT Fund RFP Screening Platform 2023-002
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), and TB Alliance.
GHIT Fund Management Team will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release August 1, 2023
Application Document Submission deadline: 10:00 am (JST) on January 15, 2024
Submit GHIT RFP Screening Platform 2023-002 Contact Form and Budget Sheet to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2023-002
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2023-002 Contact Form”
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2023-001
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), and TB Alliance.
GHIT Fund Management Team will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release February 1, 2023
Application Document Submission deadline: 10:00 am (JST) on July 14, 2023
Submit GHIT RFP Screening Platform 2023-001 Contact Form and Budget Sheet to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2023-001
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2023-001 Contact Form”
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2022-002
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), and TB Alliance.
GHIT Fund Management Team will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release August 1, 2022
Application Document Submission deadline: 10:00 am (JST) on January 13, 2023
Submit GHIT RFP Screening Platform 2022-002 Contact Form and Budget Sheet to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2022-002
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2022-002 Contact Form”
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2022-001
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), and TB Alliance.
GHIT Fund Management Team will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release February 1, 2022
Application Document Submission deadline: 10:00 am (JST) on July 15, 2022
Submit GHIT RFP Screening Platform 2022-001 Contact Form and Budget Sheet to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2022-001
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2022-001 Contact Form”
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2021-002
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), and TB Alliance.
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release August 2, 2021
Application Document Submission deadline: 10:00 am (JST) on January 14, 2022
Submit GHIT RFP Screening Platform 2021-002 Contact Form and Budget Sheet to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2021-002
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2021-002 Contact Form”
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2021-001
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), and TB Alliance.
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release February 1, 2021
Application Document Submission deadline: 10:00 am (JST) on Thursday, July 15, 2021
Submit GHIT RFP Screening Platform 2021-001 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2021-001
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2021-001 Contact Form”
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2020-002
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), and TB Alliance.
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release September 1, 2020
Intent to Apply Submission deadline: 10:00 am (JST) on Friday, January 15, 2021
Submit GHIT RFP Screening Platform 2020-002 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2020-002
Application Document N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2020-002 Contact Form"
Full Proposal Due N/A
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2020-001
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release March 2, 2020
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2020-001 Contact Form"
Full Proposal Due Submit GHIT RFP Screening Platform 2020-001 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2020-001
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2019-002
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release September 3, 2019
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2019-002 Contact Form"
Full Proposal Due Submit GHIT RFP Screening Platform 2019-002 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2019-002
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2019-001
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release April 1, 2019
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2019-001 Contact Form"
Full Proposal Due Submit GHIT RFP Screening Platform 2019-001 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2019-001
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2018-002
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2018-002 Contact Form"
Full Proposal Due Submit GHIT RFP Screening Platform 2018-002 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2018-002
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2018-001
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release June 8, 2018
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2018-001 Contact Form"
Full Proposal Due Submit GHIT RFP Screening Platform 2018-001 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2018-001Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2017-002
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release September 1, 2017
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2017-002 Contact Form"
Full Proposal Due Submit GHIT RFP Screening Platform 2017-002 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2017-002
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2017-001
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release April 1, 2017
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2017-001 Contact Form
Full Proposal Due Submit GHIT RFP Screening Platform 2017-001 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2017-001
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2016-002
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2016-002 Contact Form
Full Proposal Due Submit GHIT RFP Screening Plartform 2016-002 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2016-002
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2016-001
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release March 11, 2016
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2016-001 Contact Form
Full Proposal Due Submit GHIT RFP Screening Plartform 2016-001 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2016-001
Notification of Results To be announced to awarded applicants
GHIT Fund RFP Screening Platform 2015-002
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release September 1, 2015
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2015-002 Contact Form
Full Proposal Due Submit GHIT RFP Screening Plartform 2015-002 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2015-002
Notification of Results To be announced to awarded applicants.
GHIT Fund RFP Screening Platform 2015-001
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release March 25, 2015
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2015-001 Contact Form".
Full Proposal Due Submit GHIT RFP Screening Plartform 2015-001 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2015-001
Notification of Results To be announced to awarded applicants.
GHIT Fund RFP Screening Platform 2014-002
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release September 1, 2014
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2014-002 Contact Form".
Full Proposal Due Submit GHIT RFP Screening Plartform 2014-002 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2014-002
Notification of Results To be announced to awarded applicants.
GHIT Fund RFP Screening Platform 2014-001
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding.
RFP and Application Document
Key RFP Milestone Dates
RFP Release May 22, 2014
Intent to Apply N/A
Q&A
(RFP related questions)Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2014-001 Contact Form".
Full Proposal Due Submit GHIT RFP Screening Plartform 2014-001 Contact Form to RFPResponse@ghitfund.org
Email Subject Line: Potential Screening Platform 2014-001
Notification of Results To be announced to awarded applicants.
GHIT Fund RFP Screening Platform 2013-002
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.
The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.
Possible collaborations should include three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
Interested partnerships are required to submit the Contact Form by email to RFPResponse@ghitfund.org no later than 5:00pm JST on January 31th, 2014 (please use email subject: Potential Screening Platform 2013-002). Questions specific to this Screening Platform can only be answered with the submission of this information.
A GHIT Fund staff member will contact interested parties to discuss the funding process. If partnerships have not been identified, GHIT Fund staff are available to help facilitate communication with prospective parties. Interested organizations that are not able to form a partnership by the above deadline will be encouraged to participate in future funding calls.RFP and Application Document
GHIT Fund RFP Screening Platform 2013-001
The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs. Possible collaborations should include three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
RFP and Application Document